Breast imagers certainly had their fair share of new solutions to examine at RSNA this year. Visitors peeked at a number of full-field digital mammography systems - and gained some new insight into clinical and practice management advice when it comes to digital mammography and often integrating analog images into workflow, too. Many vendors expect digital system sales to rise now that the Digital Mammographic Imaging Screening Trial (DMIST) results are out and as analog systems age. Other vendors touted more economical CR mammo works-in-progress, which could give digital a run for the money, particularly in lower volume sites. Other highlights were multiple breast tomosynthesis works-in-progress and new breast imaging techniques designed to complement mammography.
Agfa Healthcare shared with RSNA goers its works in progress CR Mammography 85.0.
The system is designed to address the cost issue that prevents lower volume providers from implementing digital mammography and the needs of sites with backlogs and/or aging mammography equipment. The company says it has started clinical trials for the FDA approval process.
Aurora Imaging Technology, Inc. launched the Aurora 1.5T Dedicated Breast MRI System with UltraRODEO Plus fat and normal ductal tissue suppression technique, AuroraCAD integrated diagnostic software, Aurora SUPERSHIM and fully integrated MRI-guided AuroraBIOPSY functionality.
The Aurora device utilizes a specialized breast-coil design that provides an elliptical "sweet spot" to image both breasts, chest wall and axillae in a single bilateral scan, without compromise in image contrast or resolution. The continuous, homogeneous image is optimal for evaluation of both breasts, Aurora says. The device offers 1mm slices to deliver consistently high image quality.
Aurora provides biopsy functionality that accommodates all existing vacuum-assisted biopsy manufacturers, proprietary RODEO which is an established fat and normal ductal tissue suppression technique and integrated AuroraCAD software that allows for improved diagnostic and screening capabilities.
Utilizing new UltraRODEO Plus technology, the Aurora 1.5T Dedicated Breast MRI System provides specialized pulse sequences fine-tuned to suppress breast fat and normal ductal tissue. This minimizes the water and protein hot spots that can complicate MRI images. The technology also provides more detail about lesion distance, length/width, surface area and volume, enhancing the specificity of diagnosis and treatment.
AuroraSUPERSHIM is a shimming technology specifically developed for breast imaging. The process provides additional fat suppression to boost image quality, reduces hot spots and enables visualization of the axillae along with both breasts. This technology also streamlines data acquisition to reduce patient scan time.
AuroraCAD is an integrated advanced-image acquisition, processing and analysis software application. During acquisition, the software automatically recognizes and compensates for patient motion artifacts and distortions. The image analysis and processing component provides automatic, simultaneous display of multiple image views, as well as advanced 3D processing including MPR and MIP.
The Aurora 1.5T Dedicated Breast MRI System offers fully integrated interventional functionality and a wider aperture for the largest access area to the breasts for MRI-guided biopsies. The unit accommodates both core and vacuum-assisted devices and enables biopsy of multiple sites during a single procedure.
The system features a massage-type table design contoured for the female anatomy to enhance patient comfort and reduce motion artifacts. Patients enter feet first to minimize claustrophobic reactions. The 64cm gantry accommodates women up to 500 pounds and can image women with up to and including a G-cup bra size.
CompuMed, Inc. highlighted a licensing agreement with FUJIFILM Medical Systems USA.
Fuji will integrate CompuMed's OsteoGram osteoporosis screening software with its CR systems as well as future CR mammography systems. Fuji CR for Mammography (FCRm) requires FDA approval, is pending PMA review and is not yet commercially available in the U.S. Under the terms of the five year agreement, Fuji will place an initial order for 10 OsteoGram systems and then license and distribute the OsteoGram on existing and new CR systems and on future CR mammography platforms in the